dpp4i and glp 1 agonist The pharmacology of DPP-4 inhibitors is divided into primary GLP-1 Receptor Agonists Have better

Onceweekly dulaglutide versus oncedaily liraglutide in metformintreated patients with type 2 diabetes (AWARD6): a randomised, openlabel, phase 3, noninferiority trial

CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031

For anyone testing the waters before committing, the makers highlight their trial pathways as a way to reduce uncertainty

J.van der TuinS

In my experience with effective appeals and peer-to-peer review cases, success was always a result of clear, concise documentation and persistence with the argument, says Small

Funding None of the authors received any funding for this manuscript